22 completed, 5 unknown, 3 not yet recruiting, 3 recruiting. 35 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 35 | Completed 22, Unknown 5, Not yet recruiting 3, Recruiting 3, Terminated 2 |
| Phase 2 | 4 | Unknown 2, Completed 1, Not yet recruiting 1 |
Follow edoxaban: new trials by email Literature Review of edoxaban trials Research Report on edoxaban
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial Edoxaban 15 mg, Aspirin or clopidogrel - Stroke, Ischemic | Phase 3 | Recruiting | Sunnybrook Health Sciences Centre | 1204 | 2026-11-01 | 2026-10-23 |
| Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy Rivaroxaban, or Edoxaban , or Apixaban , or Dabigatran, Aspirin - Stroke, Acute Ischemic Stroke | Phase 3 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 680 | 2026-08-15 | 2026-08-05 |
| Low Dose Edoxaban in Elderly Patients With AF and a History of Stroke edoxaban, Edoxaban 30 mg - Elderly, Atrial Fibrillation (AF) | Phase 2 / Phase 3 | Not yet recruiting | National Taiwan University Hospital | 300 | 2025-04-01 | 2025-04-02 |
| Timing to Restart Direct Oral Anticoagulants After Traumatic Intracranial Haemorrhage Direct-Acting Oral Anticoagulants (used as per local standard practice) - Traumatic Intracranial Haemorrhage | Phase 3 | Recruiting | Walton Centre NHS Foundation Trust | 1084 | 2025-03-10 | 2026-06-18 |
| Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients Edoxaban - Thrombosis, Venous, Cancer | Phase 3 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 366 | 2023-11-30 | 2023-11-29 |
| AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation Acetylsalicylic acid, Apixaban, Rivaroxaban - Aortic Stenosis | Phase 3 | Completed | Oslo University Hospital | 360 | 2021-12-04 | 2026-06-09 |
| Effects of Edoxaban on Platelet Aggregation ASA, Clopidogrel, Edoxaban - SCAD, AMI | Phase 2 / Phase 3 | Completed | University of Sao Paulo | 61 | 2021-09-14 | 2025-04-27 |
| The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial DOAC, VKA - Bleeding Post Cardiac Surgery, Indication for Anticoagulation | Phase 3 | Recruiting | Population Health Research Institute | 3500 | 2021-07-18 | 2026-09-18 |
| Restart TICrH Alpha Pilot Protocol, Restarting DOACs After Traumatic Intracranial Hemorrhage Apixaban - Anticoagulants; Increased | Phase 3 | Unknown | University of Texas at Austin | 100 | 2021-07-01 | 2021-05-19 |
| Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI) Edoxaban, Warfarin Potassium, Warfarin Potassium placebo - CTEPH | Phase 3 | Completed | Kyushu University | 74 | 2021-03-23 | 2023-10-05 |
| CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19 Edoxaban Tablets, Colchicine Tablets - SARS-CoV Infection, COVID-19 | Phase 3 | Terminated | Insel Gruppe AG, University Hospital Bern | 60 | 2021-01-21 | 2022-09-08 |
| Hamburg Edoxaban for Anticoagulation in COVID-19 Study Anticoagulation Agents (Edoxaban and/or high dose LMWH), Low dose Low molecular weight heparin or Placebo - Covid19 | Phase 3 | Completed | Universitätsklinikum Hamburg-Eppendorf | 140 | 2020-11-12 | 2023-05-23 |
| MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention Dabigatran, Apixaban, Edoxaban - Stroke, Ischemic | Phase 3 | Unknown | University of Zurich | 620 | 2019-12-05 | 2023-08-16 |
| Rotterdam EDOXaban Leaflet Evaluation in Patients After Transcatheter Aortic Valve Implantation Edoxaban - Aortic Valve Stenosis | Phase 3 | Unknown | Erasmus Medical Center | 100 | 2019-08-01 | 2022-07-27 |
| PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation Apixaban Oral Tablet, Dabigatran, Edoxaban Tablets - Atrial Fibrillation, Intracerebral Hemorrhage | Phase 3 | Completed | Imperial College London | 319 | 2019-06-03 | 2025-01-13 |
| Edoxaban for the Treatment of Coagulopathy in Patients With Active Cancer and Acute Ischemic Stroke: a Pilot Study. (ENCHASE Study) Edoxaban, Enoxaparin - Correction of Cancer-related Coagulopathy With Novel Oral Anticoagulant (Edoxaban) | Phase 2 / Phase 3 | Unknown | Samsung Medical Center | 40 | 2018-06-15 | 2018-06-26 |
| Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease Edoxaban, Standard of Care (SOC) - Cardiac Disease | Phase 3 | Completed | Daiichi Sankyo | 168 | 2018-05-15 | 2022-07-26 |
| Start or STop Anticoagulants Randomised Trial (SoSTART) Apixaban, Rivaroxaban, Edoxaban - Intracranial Hemorrhages, Intracranial Hemorrhage, Hypertensive | Phase 3 | Completed | University of Edinburgh | 203 | 2018-03-28 | 2022-04-08 |
| Explore the Efficacy and Safety of edoxabaN in Patients After Heart Valve Repair or Bioprosthetic vaLve Replacement (ENAVLE Trial) Edoxaban, Warfarin, parenteral anti-coagulant (UFH) - MV(Mitral Valve) Repair | Phase 3 | Completed | Yonsei University | 220 | 2017-12-01 | 2020-01-02 |
| Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE) Edoxaban, Standard of Care - Venous Thromboembolism (VTE), Pulmonary Embolism | Phase 3 | Completed | Daiichi Sankyo | 290 | 2017-03-27 | 2025-02-28 |
Showing 20 of 35. Sign in to see all of them.
Atrial Fibrillation (11) · Venous Thromboembolism (7) · Venous Thrombosis (7) · Thrombosis (5) · Ischemic Stroke (4) · Stroke (4) · Thromboembolism (4) · Embolism (3) · Pulmonary Embolism (3) · Aortic Valve Stenosis (2) · COVID-19 (2) · Embolism and Thrombosis (2) · Heart Diseases (2) · Hemostatic Disorders (2) · Intracranial Hemorrhages (2)
Daiichi Sankyo (7) · Daiichi Sankyo Co., Ltd. (6) · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (2) · Atrial Fibrillation Network (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Erasmus Medical Center (1) · Imperial College London (1) · Insel Gruppe AG, University Hospital Bern (1) · Kyushu University (1) · National Taiwan University Hospital (1) · Oslo University Hospital (1) · Population Health Research Institute (1) · Samsung Medical Center (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Sunnybrook Health Sciences Centre (1)
United Kingdom (12) · Germany (11) · Spain (11) · France (10) · Italy (10) · Japan (10) · Belgium (9) · Hungary (9) · Netherlands (9) · Canada (8) · South Korea (8) · Austria (7) · Poland (7) · Taiwan (7) · Ukraine (7)
Takeshi Fuji (3) · Andreas Gotte, Prof., MD (1) · Catherine McMahon (1) · Emilie Belley-Cote, MD, MSc (1) · Gang Zhao, M.D. (1) · Kohtaro Abe (1) · Min Lou, PhD, MD (1) · Mira Katan, Prof.Dr.med. (1) · Nicolas M Van Mieghem, MD, PhD (1) · Pascal Vranckx, MD (1) · Paulus Kirchhof, Prof. Dr. (1) · Roland E Veltkamp, FESO (1) · Rustam Al-Shahi Salman, MA PhD FRCP (1)
PMID 36700520, PMID 27980462, PMID 34022170, PMID 40925065, PMID 20934556, PMID 21861537, PMID 22398655, PMID 23991658, PMID 24251359, PMID 24302269, PMID 24680549, PMID 24947287, PMID 25104527, PMID 25294589, PMID 25653574, PMID 25769357, PMID 25769361, PMID 25965706, PMID 26179767, PMID 26271200, PMID 26908401, PMID 27207971, PMID 27284271, PMID 27358434, PMID 27387994, PMID 27402235, PMID 27476789, PMID 27570090, PMID 27590218, PMID 27609678, PMID 27706467, PMID 28077507, PMID 28302288, PMID 28666993, PMID 28689179, PMID 28862934, PMID 29231094, PMID 29248859, PMID 29421002, PMID 29663464, PMID 29748353, PMID 29947751, PMID 29967197, PMID 30172099, PMID 30236308, PMID 30586727, PMID 31492505, PMID 31597460, PMID 31777160, PMID 31986264
2016 (5), 2014 (1), 2015 (1), 2017 (1), 2018 (1)